General Oncology
Abid Ansari serves as the Chief Financial Officer at General Oncology since December 2024, while also functioning as a Strategic Financial Advisor for Ansari Consulting LLC since June 2020, focusing on finance, accounting, fundraising, marketing, and operations. Previously, Ansari held the CFO position at Artios Pharma Ltd, leading a successful $153 million Series C financing and transitioning the company to public status with SOX404 compliance. As CFO at Precision BioSciences, Inc., Ansari led a notable $146 million IPO, representing the company at key healthcare conferences. With substantial experience at GSK, Ansari contributed to multiple significant deals in business development and led a global team for R&D investment analytics. Ansari holds a B.S. in Chemical Engineering and an MBA in Finance and Operations Management from Purdue University.
This person is not in any teams
This person is not in any offices
General Oncology
General Oncology is developing a pipeline of treatments for solid metastatic cancers and cancers of the blood. They have a clinical trial underway for an investigational treatment for BRCA-related metastatic pancreatic cancer.General Oncology is sponsoring a clinical trial (Clinical Trial GO-1) for its investigational treatment for BRCA-relatedmetastatic pancreatic cancer. The treatment involves two cycles of chemotherapy using melphalan, BCNU, vitamin B12b, and vitamin C, along with two stem cell transplants to reverse bone marrow suppression. The trial is currently open for enrollment.